Blog
RSS FeedPosted by Michael Wonder on 18 Jun 2021
Outcomes of the May 2021 PBAC intracycle meeting
18 June 2021 - The outcomes from the May 2021 PBAC meeting are now available. ...
Posted by Michael Wonder on 16 Jun 2021
TLV receives a new assignment for precision medicine and advanced therapy drugs
15 June 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, is commissioned by the government to continue the ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 15 Jun 2021
How the patient voice is becoming vital for drug approval
14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...
Posted by Michael Wonder on 14 Jun 2021
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...
Posted by Michael Wonder on 14 Jun 2021
NICE to reassess Kyowa Kirin’s Poteligeo
14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...
Posted by Michael Wonder on 10 Jun 2021
Astellas’ Xtandi bags NICE approval in prostate cancer
10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...
Posted by Michael Wonder on 10 Jun 2021
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...
Posted by Michael Wonder on 10 Jun 2021
Updated financial estimates workbook
10 June 2021 - An updated version of the Utilisation and Cost Model workbook and User Manual is now available to ...
Posted by Michael Wonder on 10 Jun 2021
Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications
7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...
Posted by Michael Wonder on 08 Jun 2021
NICE recommends Tecentriq for first-line NSCLC
7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...
Posted by Michael Wonder on 07 Jun 2021
SMC - June 2021 decisions
7 June 2021 - Advice on five new medicines for use in conditions including advanced gastric cancer and chronic lymphocytic leukaemia ...
Posted by Michael Wonder on 07 Jun 2021
ICER issues statement on the FDA’s approval of aducanumab for Alzheimer’s disease
7 June 2021 - The ICER believes that the FDA, in approving aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s ...
Posted by Michael Wonder on 06 Jun 2021
NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness
3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...
Posted by Michael Wonder on 04 Jun 2021
NICE turns down GSK's IV Benlysta for systemic lupus
4 June 2021 - NICE has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on ...